The listing application for the new class 1 drug Malayacid pyridorate and tablets of Hengrui Pharmaceuticals has been reviewed
-
Last Update: 2020-06-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, C
FDA(official website information shows that Jiangsu HengruiPharmaceutical(class
new drug(Malay acid pyrideinandini and tablets have been reviewed, is expected to be approved for listing, Hengrui will soon harvest another heavyproduct()about Malay acid pyridoxandinibMalay acid pyridoxinib is a class 1.1 EGFR/HER2 inhibitor developed by Hengrui Pharmaceuticals and was approved for clinical treatment in China in May 2012In the domestic innovationdrug(the declaration record, Shenzhen micro-core bio-sidedbena mine is the first to directly declare the production of phase II clinical data innovative drugs, Hengrui Pharmaceuticals this innovative drug is the secondthe listing application for Malayapyrinib and tablets was accepted by CDE in August 2017, and in just one month was incorporated into the 23rd batch of pharmaceuticalto be included in the priority review
process published by CDE on the grounds of "obvious clinical value and major special projects" (list, which took one year to complete the listing approval process, and the progress of the declaration exceeded expectations."
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
